RT Journal Article
SR Electronic
T1 Type 2 Diabetes and Risk of Early-Onset Colorectal Cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.02.21257972
DO 10.1101/2021.06.02.21257972
A1 Li, Zitong
A1 Chen, Hanyu
A1 Fritz, Cassandra D.L
A1 Zheng, Xiaobin
A1 Zong, Xiaoyu
A1 Nickel, Katelin B.
A1 Tipping, Andrew
A1 Nguyen, Long H.
A1 Chan, Andrew T.
A1 Giovannucci, Edward L.
A1 Colditz, Graham A.
A1 Olsen, Margaret A.
A1 Campbell, Peter T.
A1 Davidson, Nicholas O.
A1 Fields, Ryan C.
A1 Cao, Yin
YR 2021
UL http://medrxiv.org/content/early/2021/06/07/2021.06.02.21257972.abstract
AB Objective Early-onset colorectal cancer (CRC) is increasing in many developed countries. Type 2 diabetes mellitus has increased substantially in younger adults; however, its role in early-onset CRC remains unidentified.Design We conducted a claims-based nested case-control study using IBM® MarketScan® Commercial Database (2006-2015). Incident early-onset CRC diagnosed at ages 18-49 were identified by ICD-9-CM diagnosis code, and the first coded diagnostic pathology date was assigned as the index date. Controls were frequency matched with cases. Type 2 diabetes, stratified by severity, was identified through ICD-9-CM using the Klabunde algorithm. Multivariate logistic regressions were used to estimate odds ratios (ORs) and 95% confidence intervals (Cls).Results A total of 6001 early-onset CRC and 52104 controls were included. Type 2 diabetes was associated with an increased risk of early-onset CRC (5.0% in cases vs. 3.7% in controls; OR 1.24; 95% CI 1.09 to 1.41). The positive association was more pronounced for uncontrolled (OR 1.37; 95% CI 1.12 to 1.67) or complicated (OR 1.59; 95% CI 1.08-2.35) type 2 diabetes compared to controlled diabetes (OR 1.13; 95% CI 0.94 to 1.36). The positive association was driven by proximal (OR 1.35; 95% CI 1.03 to 1.77) and distal (OR 1.67; 95% CI 1.30 to 2.15) colon cancer but not rectal cancer.Conclusions Individuals with type 2 diabetes have a higher risk of early-onset CRC, with stronger associations for uncontrolled/complicated diabetes. The rising prevalence of type 2 diabetes among younger adults in the US may partially contribute to the increasing incidence of early-onset CRC.Competing Interest StatementAndrew T. Chan previously served as a consultant for Janssen Pharmaceuticals, Pfizer, Inc, and Bayer Pharma AG for work unrelated to the topic. Yin Cao previously served as a consultant for Geneoscopy for work unrelated to the topic. The remaining authors disclose no conflicts.Funding StatementThis work was supported by the National Institutes of Health (NIH) grant P30CA091842. The Center for Administrative Data Research is supported in part by the Washington University Institute of Clinical and Translational Sciences grant UL1 TR002345 from the National Center for Advancing Translational Sciences (NCATS) of the NIH and R24 HS19455 through the Agency for Healthcare Research and Quality (AHRQ). CDF is supported by T32 DK007130. XBZ was supported by the International Program for PhD candidates, Sun Yat-sen University. ATC is Stuart and Suzanne Steele MGH Research Scholar.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board (IRB) at Washington University in St. Louis decided that this project was not considered to meet federal definitions under the jurisdiction of an IRB and therefore falls outside the purview of the Human Research Protection Office.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData were obtained from a third party and are not publicly available.CIconfidence intervalCRCcolorectal cancerFOBTfecal occult blood testGIgastrointestinalHCUP CCSHealthcare Cost and Utilization Project’s Clinical Classification SoftwareHMOHealth Maintenance OrganizationIBDinflammatory bowel diseasesIQRinterquartile rangeORodds ratioPPOPreferred Provider OrganizationSDstandard deviation